Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sagent Pharmaceuticals has raised a capital of $30 million in an extension of second Series A financing with pre-existing and new strategic investors. The company aims to use the amount to support strategic business objectives, product launches and development activities. The round was led by Vivo Ventures.
Subscribe to our email newsletter
Jeffrey M. Yordon, CEO of Sagent, said: “Since our inception in 2006, Sagent has successfully executed its strategy by filing more than 70 aNDAs to date, with more than 20 products expected in the market by year end. We appreciate our investors’ continued confidence and commitment to Sagent.”
Sagent is engaged in the development, manufacturing and marketing of pharmaceutical products, with focus on injectable products. The company’s product portfolio constitutes more than 200 products in various stages of development.